Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced ...

RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.

Prothena Corporation plc kept at Hold after mixed phase 2 results; key phase 3 readouts expected 2029. Click for this updated ...

Lithium—a decades-old treatment for bipolar disorder—may hold potential neuroprotective benefits beyond mood stabilization.

Long-term care facility residents in Warsaw, Poland, showed poor oral health and had a median number of missing teeth ranging ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom ...

Topline results from the MUSCLE study indicate that ulviprubart did not meet its primary endpoint of mean change in inclusion ...

Nearly 70% of patients with mild-to-moderate Crohn’s disease following a 5-day-per-month fasting-mimicking diet achieve a ...

A clinical trial suggests that low-dose lithium may slow the decline of verbal memory in older adults with mild cognitive impairment and amyloid-beta.

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen ...

The FDA is expected to decide on treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, ...